James Loerop - Feb 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 1, 2024
Transactions value $
-$7,705
Form type
4
Date filed
2/5/2024, 07:29 PM
Previous filing
Aug 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +11.3K +51.87% 32.9K Feb 1, 2024 Direct F1
transaction ACRS Common Stock Tax liability -$4.62K -3.85K -11.7% $1.20 29.1K Feb 1, 2024 Direct F2
transaction ACRS Common Stock Options Exercise +7.5K +25.79% 36.6K Feb 1, 2024 Direct F1
transaction ACRS Common Stock Tax liability -$3.08K -2.57K -7.02% $1.20 34K Feb 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -11.3K -33.33% $0.00 22.5K Feb 1, 2024 Common Stock 11.3K Direct F1, F3
transaction ACRS Restricted Stock Unit Options Exercise $0 -7.5K -25% $0.00 22.5K Feb 1, 2024 Common Stock 7.5K Direct F1, F4
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +207K $0.00 207K Feb 1, 2024 Common Stock 207K $1.20 Direct F5
transaction ACRS Restricted Stock Units Award $0 +59K $0.00 59K Feb 1, 2024 Common Stock 59K Direct F1, F6
transaction ACRS Restricted Stock Units Award $0 +148K $0.00 148K Feb 1, 2024 Common Stock 148K Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F6 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F7 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.